WuXi AppTec, a global provider of R&D and manufacturing enabling services in the pharma/biopharma and medical device industries, has completed the acquisition of OXGENE, a UK-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies.
 
OXGENE will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) business unit. OXGENE will retain its name and will be WuXi ATU’s first facility in Europe.
 
OXGENE offers discovery and biomanufacturing solutions to the cell and gene therapy industries through novel technologies and contract research solutions. It also provides manufacturing systems that deliver exceptional scalability. OXGENE’s novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing are designed to simplify cell and gene therapy manufacturing and significantly reduce costs.